Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

Figure 1 Hematoxylin and eosin staining photomicrographs of a right lung tumor tissue biopsy. A: Original magnification (×20); B: Original magnification (×40).

Figure 2 Next-generation sequencing revealed two concurrent MET fusions with different fusion partners, MET-CDR2 and KIF5B-MET. A: Images from the Integrative Genomics Viewer demonstrating the chromosomal rearrangement involving MET (chromosome 7, sequencing reads with gray background) and CDR2 (chromosome 16, sequencing reads with blue background); B: KIF5B (chromosome 10, sequencing reads with blue background). Illustrations below demonstrate the protein structure resulting from the gene fusions indicating the breakpoints of the nearby exons.

Figure 3 Clinical efficacy of crizotinib treatment in a patient with KIF5B-MET and MET-CDR2-rearranged, poorly differentiated lung cancer. A: Thoracic computed tomographic image at baseline; B: 1 mo after initiating crizotinib therapy; C and D: After disease progression and another 2 mo later in May, 2019.